Stéphane Ramin-Mangata

Stéphane Ramin-Mangata

Auto-generated profile, based on publicly available information

Stéphane Ramin-Mangata

UMR PVBMT, University of Reunion Island, Saint-Pierre, Reunion Island 97410, France

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
BABenoit J. Arsenault
Benoit J. Arsenault
FPFrancine Petrides
Francine Petrides
FTFatiha Tabet
Fatiha Tabet
WBWeihang Bao
Weihang Bao
GHG. Kees Hovingh
G. Kees Hovingh
GLGilles Lambert
Gilles Lambert

31 May 2018 in Clinical Science
Verified
Journal Article
Closed access
PDF file
MCMikaël Croyal
Mikaël Croyal
TTThi-Thu-Trang Tran
Thi-Thu-Trang Tran
RBRose Hélène Blanchard
Rose Hélène Blanchard
JBJean-Christophe Le Bail
Jean-Christophe Le Bail
EVElise F. Villard
Elise F. Villard
EGEtienne Guillot
Etienne Guillot
Therapeutic antibodies targeting proprotein convertase subtilisin kexin type 9 (PCSK9) (e.g. alirocumab) lower low-density lipoprotein cholesterol (LDL-C) and lipoprotein (a) [Lp(a)] levels in clinical trials. We recently showed that PCSK9 enhances apolipoprotein(a) [apo(a)] secretion from primary human hepatocytes but does not affect Lp(a) cellular uptake. Here, we aimed to determine how PCSK9 neutralization modulates Lp(a) levels in vivo. Six nonhuman primates (NHP) were treated with alirocumab or a control antibody (IgG1) in a crossover protocol. After the lowering of lipids reached steady state, NHP received an intravenous injection of [2H3]-leucine, and blood samples were collected sequentially over 48 h. Enrichment of apolipoproteins in [2H3]-leucine was assessed by liquid chromatography–tandem mass spectrometry (LC–MS/MS). Kinetic parameters were calculated using numerical models with the SAAMII software. Compared with IgG1, alirocumab significantly reduced total cholesterol (TC) (−28%), LDL-C (−67%), Lp(a) (−56%), apolipoprotein B100 (apoB100) (−53%), and apo(a) (−53%). Alirocumab significantly increased the fractional catabolic rate of apoB100 (+29%) but not that of apo(a). Conversely, alirocumab sharply and significantly reduced the production rate (PR) of apo(a) (−42%), but not significantly that of apoB100, compared with IgG1, respectively. In line with the observations made in human hepatocytes, the present kinetic study establishes that PCSK9 neutralization with alirocumab efficiently reduces circulating apoB100 and apo(a) levels by distinct mechanisms: apoB primarily by enhancing its catabolism and apo(a) primarily by lowering its production.

1 January 2018 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
VBValentin Georges Marcel Blanchard
Valentin Georges Marcel Blanchard
SRStéphane Ramin-Mangata
Stéphane Ramin-Mangata
SBStéphanie Billon-Crossouard
Stéphanie Billon-Crossouard
AAAudrey Aguesse
Audrey Aguesse
MDManon Durand
Manon Durand
MCMikael Croyal
Mikael Croyal
Valentin Blanchard, Stéphane Ramin-Mangata, Stéphanie Billon-Crossouard, Audrey Aguesse, Manon Durand, Kevin Chemello, Brice Nativel, Laurent Flet, Maud Chétiveaux, David Jacobi, Jean-Marie Bard, Khadija Ouguerram, Gilles Lambert, Michel Krempf, Mikaël Croyal

20 January 2017 in Clinical Science
Verified
Journal Article
Closed access
PDF file
GLGilles Lambert
Gilles Lambert
ATAurélie Thedrez
Aurélie Thedrez
MCMikaël Croyal
Mikaël Croyal
SRStéphane Ramin-Mangata
Stéphane Ramin-Mangata
DCDavid Couret
David Couret
EGEtienne Guillot
Etienne Guillot
Since 2012, clinical trials dedicated to proprotein convertase subtilisin kexin type 9 (PCSK9) inhibition with monoclonal antibodies (mAbs) have unambiguously demonstrated robust reductions not only in low-density lipoprotein (LDL) cholesterol (LDL-C) but also in lipoprotein (a) [Lp(a)] levels. The scientific literature published prior to those studies did not provide any evidence for a link between PCSK9 and Lp(a) metabolism. More recent investigations, either in vitro or in vivo, have attempted to unravel the mechanism(s) by which PCSK9 mAbs reduce circulating Lp(a) levels, with some showing a specific implication of the LDL receptor (LDLR) in Lp(a) clearance whereas others found no significant role for the LDLR in that process. This elusive pathway appears clearly distinct from that of the widely prescribed statins that also enhance LDLR function but do not lower circulating Lp (a) levels in humans. So how does PCSK9 inhibition with mAbs reduce Lp(a)? This still remains to be established.

1 January 2020 in Atherosclerosis
Verified
Journal Article
Closed access
SRStéphane Ramin-Mangata
Stéphane Ramin-Mangata
MWMatthieu Wargny
Matthieu Wargny
MPMatthieu PICHELIN
Matthieu PICHELIN
CMCédric Le May
Cédric Le May
ATAurélie Thédrez
Aurélie Thédrez
BCBertrand Cariou
Bertrand Cariou

1 April 2022 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Open access
PDF file
SCStefan Coassin
Stefan Coassin
KCKevin Chemello
Kevin Chemello
IKIlya Khantalin
Ilya Khantalin
LFLukas Forer
Lukas Forer
PDPatricia Döttelmayer
Patricia Döttelmayer
GLGilles Lambert
Gilles Lambert
Background: Lp(a) (lipoprotein [a]) is a highly atherogenic lipoprotein strongly associated with coronary artery disease (CAD). Lp(a) concentrations are chiefly determined genetically. Investigation of large pedigrees with extreme Lp(a) using modern whole-genome approaches may unravel the genetic determinants underpinning this pathological phenotype. Methods: A large family characterized by high Lp(a) and increased CAD incidence was recruited by cascade screening. Plasma lipids, lipoproteins, and apolipoproteins concentrations, as well as the size of apo(a) isoforms, were determined enzymatically by high-resolution mass spectrometry and Western blot, respectively. Whole-exome sequencing was performed to search for rare defects in modifier genes. Genetic risk scores (GRS) for Lp(a) and CAD were calculated and their discriminative power was assessed. Results: Seventeen individuals displayed extreme Lp(a) levels including 6 with CAD. Whole-exome sequencing showed no hint for genetic defects outside the LPA locus. The extreme Lp(a) phenotype segregated with the presence of a short apo(a) isoform containing 21 Kringle IV domains. This allele was characterized by the presence of three rare strongly Lp(a) increasing single nucleotide polymorphisms and a significantly increased load of oxidized phospholipids per Lp(a) particle. An Lp(a) GRS consisting of 48 single nucleotide polymorphisms that represent 2001 genome-wide significant LPA single nucleotide polymorphisms, efficiently captured the hyper-Lp(a) phenotype and discriminated affected and nonaffected individuals with great accuracy. The genome-wide GRS for CAD, encompassing 6.6 million single nucleotide polymorphisms, was very high for most family members (>97.5 percentile of the reference population), but this observation was no longer valid when the contribution of the LPA locus was omitted. Conclusions: High-Lp(a) phenotypes can be successfully captured using the Lp(a) GRS even among closely related family members. In hyper-Lp(a) individuals, LPA can be a major locus driving a very high CAD GRS. This underpins the large contribution of the LPA locus to the cardiovascular genetic risk in families.